Drugs & OTC

Cann Global Limited (ASX:CGB) Further Asian Business Expansion

🕔10/28/2019 8:31:39 AM

The Board of Cann Global Limited (ASX:CGB) is pleased to announce that it is expanding the Company's current APAC/Asian presence and business activities, and has incorporated a further Asian focused subsidiary, Cann Global Asia Pty Ltd.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔10/23/2019 8:23:31 AM

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the 10th Annual Australian Microcap Investment Conference, held in Melbourne, VIC.

Read Full Article

Anatara Lifesciences (ASX:ANR) "The Health Kick" podcast with Tim Boreham

🕔10/18/2019 9:52:35 AM

Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Financial Report

🕔10/17/2019 10:27:27 AM

Forecast expenditure for the December 2019 quarter is anticipated to increase as the Company advances the development of its Gastrointestinal Reprogramming (GaRP) dietary supplement. A refund from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme is anticipated to be received in December 2019.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Reports Statistically Significant Animal Studies

🕔10/14/2019 10:13:52 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to report statistically significant efficacy data from its in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Annual Report to Shareholders

🕔10/11/2019 10:08:13 AM

Anatara Lifesciences Ltd's (ASX:ANR) lead human health product, GaRP, is being developed to specifically target two human gastrointestinal (GI) disorders, Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), where there is a significant unmet medical need.

Read Full Article

Cann Global Limited (ASX:CGB) Annual Report to Shareholders

🕔9/30/2019 8:20:47 AM

Cann Global Ltd (ASX:CGB) ("CGB" or "the Company") presents the annual report on activities for the year ending 30 June 2019.

Read Full Article